Search Results
Your search for ASCO,ASCO matches 20612 pages
Showing 1551 - 1600Diversity May Play a Key Role in Black Patients’ Trust of Videos About Prostate Cancer
Black patients may be 1.6 times more likely to believe medical information presented by a Black speaker than information presented by a White speaker, according to a new study published by Loeb et al in JAMA Network Open. The findings highlight the importance of increasing racial diversity among...
SSO Names Chandrakanth Are, MBBS, MBA, Chief Executive Officer of Global Forum of Cancer Surgeons
As a member of the Global Forum of Cancer Surgeons, the Society of Surgical Oncology (SSO) is pleased to announce that Chandrakanth Are, MBBS, MBA, FSSO, FRCS, FACS, has been named Chief Executive Officer of the Global Forum of Cancer Surgeons. Dr. Are holds the title of Jerald L. and Carolynn J....
ASCO Remembers Former Board of Directors Member and Radiation Oncologist A. William Blackstock, Jr, MD, FASCO
ASCO is deeply saddened by the death of A. William Blackstock, Jr, MD, FASCO, who served on the Society’s Board of Directors from 2018 to 2022. Dr. Blackstock passed away on June 18, 2023, from complications of prostate cancer. He was 60 years old. “We mourn the passing of a friend and colleague...
Study of Cancer Metastasis Receives $35 Million Boost at Johns Hopkins Medicine
With a $35 million gift from researcher, philanthropist, and race car driver Theodore Giovanis, FHFMA, MBA, scientists at Johns Hopkins Medicine will study the biologic roots of the most fatal aspect of cancer: how it metastasizes through the body. The contribution, which is a 15-year commitment,...
Damon Runyon Names Physician-Scientist Awardees
Three scientists who are researching novel approaches to the treatment of cancer have been named the 2023 recipients of the Damon Runyon Physician-Scientist Training Award: Nicole M. Cruz, MD; Mounica Vallurupalli, MD; and Nina Weichert-Leahey, MD. The awardees were selected through a highly...
Berberine
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on the use of...
Alfredo Quiñones-Hinojosa, MD: From Migrant Farm Worker to Neurosurgeon in Search of a Cure for Brain Cancer
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with neurosurgeon Alfredo Quiñones-Hinojosa, MD, FAANS, FACS, the James C. and Sarah K. Kennedy Dean of Research, Monica Flynn Jacoby Chair of Neurologic Surgery, and William J. and Charles...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Allison Institute Announces Appointment of Inaugural Members
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center has announced the appointment of its first members, including pioneering researchers who have made notable contributions to science as well as rising stars on the path toward important breakthroughs. This group will ...
Expert Point of View: Kathleen Moore, MD, MS
“I think the NOW trial is a great study,” said Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Oklahoma City, who shared her thoughts on the trial with The ...
Study Examines Impact of Modified Treatment Protocols on Survival in Pediatric Patients With ALL
The 5-year survival rate of pediatric patients with acute lymphoblastic leukemia (ALL) has continued to increase to 94%, according to a new study published by Pieters et al in the Journal of Clinical Oncology. Background ALL is the most common form of pediatric cancer in the Netherlands—with about...
Neoadjuvant and Adjuvant GVAX Plus Nivolumab and Urelemab May Increase Immune Response in Patients With Resectable Pancreatic Cancer
A combination of the pancreatic cancer vaccine GVAX, the immune checkpoint inhibitor nivolumab, and the anti-CD137 agonist antibody urelemab may be safe and increase the amount of immune T cells in the tumors of patients with operable pancreatic cancer when given 2 weeks prior to surgical tumor...
Expert Point of View: Barbara Burtness, MD
Barbara Burtness, MD, the Anthony N. Brady Professor of Medicine and Chief Translational Research Officer at Yale Cancer Center, New Haven, featured the CONTINUUM study at the head and neck cancer session on Highlights of the Day during the 2023 ASCO Annual Meeting. She noted the study’s premise...
CONTINUUM: In Locally Advanced Nasopharyngeal Cancer, Addition of Sintilimab to Chemoradiotherapy Offers Benefit
The addition of the PD-1 inhibitor sintilimab to standard induction chemotherapy and chemoradiotherapy resulted in a significant improvement in 3-year event-free survival, a manageable safety profile, and comparable quality of life in high-risk, locally advanced nasopharyngeal carcinoma vs standard ...
Cetuximab Plus Radiotherapy Shows Activity in Patients With Locally Advanced Cutaneous Squamous Cell Carcinoma
Investigators have discovered that cetuximab in addition to concurrent radiotherapy may be safe and effective at treating patients with locally advanced cutaneous squamous cell carcinoma, according to a recent study published by Chang et al in Oncotarget. Treatment for locally advanced cutaneous...
APOBEC3A Protein May Be Linked to Drug Resistance in Patients With NSCLC
Researchers have uncovered how non–small cell lung cancer (NSCLC) tumors may develop drug resistance over time and identified the APOBEC3A protein as a potential target for novel cancer therapeutics, according to a study published by Isozaki et al in Nature. The findings point to potential...
Aspartame Hazard and Risk Assessment Results Released by IARC and JECFA
Assessments of the health impacts of the nonsugar sweetener aspartame were released today by the International Agency for Research on Cancer (IARC) and the World Health Organization (WHO)/Food and Agriculture Organization (FAO) Joint Expert Committee on Food Additives (JECFA). Citing “limited...
Pembrolizumab-Based Combination Therapies May Improve Outcomes in Advanced NSCLC
Researchers have revealed that combining pembrolizumab with other treatments may reduce the size of target tumors, resulting in a higher response rate for patients with advanced non–small cell lung cancer (NSCLC), according to a recent study published by Gutierrez et al in Nature Medicine. “We are...
Decimation of Gut Bacteria and Chemotherapy-Induced Weight Gain in Patients With Breast Cancer
Researchers have uncovered a potential link between chemotherapy-induced changes to gut bacteria and weight gain seen in patients with breast cancer, according to a recent study published by Walker et al in BMC Medicine. The findings may help to identify approaches to avoid obesity-related diseases ...
Jennifer R. Brown, MD, PhD, on CLL: Resistance to Pirtobrutinib in Pretreated Disease
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase I/II findings from the Bruin study of resistance to pirtobrutinib in patients with covalent BTK inhibitor–pretreated chronic lymphocytic leukemia (CLL). The aim of the study was to explore the genomic evolution of...
MLH1 Methylation Status and Screenings for Colorectal or Endometrial Cancer
New research could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, according to a novel study published by Hitchins et al in JNCCN–Journal of the National Comprehensive Cancer Network. The findings suggest that the guidelines leave a...
New Tool May Help Physicians Pinpoint Gaps in Hematologic Malignancy Awareness
The novel Blood Cancer Awareness Measure tool could identify gaps in the public's knowledge of hematologic malignancy symptoms and aid in the development of future awareness campaigns designed to save lives, according to a new study published by Boswell et al in BMC Cancer and Whitaker et al in...
Expert Point of View: Kevin Kalinsky, MD, MS
Session co-moderator Kevin Kalinsky, MD, MS, the Louisa and Rand Glenn Family Chair in Breast Cancer Research, Director of the Glenn Family Breast Center, and Director of Breast Medical Oncology at the Winship Cancer Institute of Emory University, Atlanta, offered his thoughts on PHERGain to The...
PHERGain: Adapted-Response Trial Guides Treatment With Dual HER2 Blockade Alone
The phase II PHERGain trial, which employed a response-adapted strategy in the treatment of early-stage, HER2-positive breast cancer, has shown promising results for the selective use of HER2 blockade and de-escalation of chemotherapy.1 Nearly all patients assigned to skip chemotherapy prior to...
Overweight and Obese BMI May Be Linked to Adverse Treatment Outcomes in AYA Patients With ALL
An elevated body mass index (BMI) could potentially be associated with inferior treatment outcomes in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL), according to a new study published by Shimony et al in Blood Advances. The findings may demonstrate the impact of...
Changing How Immune Checkpoint Inhibitors Are Delivered Could Reduce Costs by 14%, Study Finds
Investigators have found that millions of dollars could be saved annually across the Veterans Health Administration by reconsidering how immune checkpoint inhibitors are delivered, according to a new study published by Bryant et al in Health Affairs. The findings suggested that if vials of immune...
Fecal Microbiota Transplants Show Potential in Improving Melanoma Treatment
Researchers have found that fecal microbiota transplants from healthy donors may be safe and show potential in improving response rates to immunotherapy in patients with advanced melanoma, according to a phase I study published by Routy et al in Nature Medicine. Background While immunotherapy...
Patients With Prostate Cancer May Face High Rates of Financial Toxicity
About 50% of patients with metastatic prostate cancer may experience financial hardship as a result of their treatment, according to a new study published by Joyce et al in The Journal of Urology. Background "Our most significant finding may be that patients experience financial toxicity despite...
Expert Point of View: Erminia Massarelli, MD, PhD, MS
The invited discussant of the VERSATILE-002 and CUE-101-01 trials, Erminia Massarelli, MD, PhD, MS, said both are examples of a growing interest in evaluating immunotherapeutic strategies and treatment sequences in early-stage head and neck squamous cell cancer as well as in metastatic disease. Dr. ...
Novel HPV-Targeted Agents Boost Efficacy of Pembrolizumab in Head and Neck Cancer, Two Studies Show
Immunotherapeutics that target human papillomavirus (HPV) genotype 16 appear to boost the activity of pembrolizumab in advanced head and neck squamous cell carcinoma. Two examples were presented in posters at the 2023 ASCO Annual Meeting.1,2 The phase II VERSATILE-002 trial evaluated PDS0101,...
I Didn’t Want My Past to Become My Future
When I felt a large mass in my left breast as I was drying off from a shower on Thanksgiving Day, in 2007, I instinctively knew it was cancer. My mother had been diagnosed with breast cancer when she was 38, just 7 years older than I was at the time, and died 4 years later. I was 6 when she was...
Targeting Depressive Symptoms in Younger Breast Cancer Survivors
Guest Editor’s Note: Psychological distress is highly prevalent in women diagnosed with premenopausal breast cancer and has a significant negative impact on their quality of life. Thus, effective strategies are urgently needed to reduce the symptom burden. In this installment of The ASCO Post’s...
Assessing Geriatric Oncology Practice in Portugal
The global population is aging rapidly. Currently, there are more than 703 million people worldwide aged 65 and older, representing 9.1% of the global population. It is estimated that this percentage will grow to 15.9%—1.5 billion people—by 2050.1 And with that growing aging population will come...
ASCO Updates Guideline on Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Results from a series of randomized, controlled trials have prompted an update to the ASCO guideline on venous thromboembolism (VTE) prophylaxis and treatment in patients with cancer. The revised guideline, which had last been updated in 2019, is available from the Journal of Clinical Oncology.1...
How ASCO’s 2023 Breakthrough Meeting Is Putting a Spotlight on Cutting-Edge Advances in Cancer Care Technology and Innovation
After a 4-year hiatus because of the COVID-19 pandemic, ASCO’s Breakthrough meeting is returning to Asia from August 3–5, 2023, in Yokohama, Japan, and will also be livestreamed (https://conferences.asco.org/breakthrough/welcome). Launched in 2019 in Bangkok, Thailand, “Breakthrough is ASCO’s...
A Telephone-Based Weight-Loss Intervention Induced Clinically Meaningful Weight Loss in Patients With Breast Cancer and Overweight or Obesity
Jennifer A. Ligibel, MD, FASCO, Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, and colleagues conducted a randomized study to evaluate the impact of a telephone-based ...
Health Systems Strengthening Approach in the United States–Mexico Border Region Improved 5-Year Survival for Children With ALL
The implementation of a collaborative program between North American and Mexican medical institutions to achieve sustainable, high-quality care at a public hospital in the United States–Mexico border region for children with acute lymphoblastic leukemia (ALL) has resulted in significant improvement ...
Expert Point of View: Caron Jacobson, MD
Caron Jacobson, MD, shared some comments on ZUMA-7 with The ASCO Post. She called ZUMA-7 “an extremely important study to advance the care of high-risk early relapsing or primary refractory large B-cell lymphoma after front-line chemoimmunotherapy.” Dr. Jacobson is Assistant Professor of Medicine...
ZUMA-7: Primary Overall Survival Analysis Supports Axicabtagene Ciloleucel as Second-Line Therapy in Advanced Lymphoma
In the primary overall survival analysis of ZUMA-7, second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplantation (auto-HCT) in patients with early relapsed or refractory large B-cell lymphoma....
A European Leader in Surgical Oncology, Isabel T. Rubio, MD, PhD, Shares Her Story and Sheds Light on the Challenges Ahead
In this installment of The ASCO Post’s Global Oncology series, guest editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Isabel T. Rubio, MD, PhD, Head of Breast Surgical Oncology at Clinica Universidad de Navarra, Madrid. Dr. Rubio is active in many societies and is a founding member and...
Lobular vs Ductal Breast Cancer: Distinctions in Management
As a relatively rare subtype, lobular breast cancer is not well understood by many oncologists. At the 2023 Miami Breast Cancer Conference, Tari A. King, MD, FASCO, described how it differs from its more common counterpart, ductal breast cancer, in terms of characteristics, prognosis, and optimal...
CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer
At extended follow-up, lenvatinib plus pembrolizumab showed sustained superiority over sunitinib for overall and progression-free survival as first-line treatment for advanced renal cell carcinoma.1 The majority of the benefit was observed in intermediate- and poor-risk subgroups, according to the...
Pathology Assessment During Mastectomy and Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer
Axillary management decisions made during surgery may be associated with aggressive treatment of limited nodal disease, according to data presented at a press briefing at the 2023 American Society of Breast Surgeons Annual Meeting.1 Results of a large National Cancer Database study revealed that...
Expert Point of View: Kohei Shitara, MD and Bradley Alexander McGregor, MD
At the ASCO session on the phase II DESTINY-PanTumor02 trial on T-DXd, the invited discussant, Kohei Shitara, MD, commented: “As expected, this trial demonstrated a very impressive response rate and duration of response” and “showed T-DXd [fam-trastuzumab deruxtecan-nxki] to be a potential new...
DESTINY-PanTumor02: Is T-DXd Heading for Tumor-Agnostic Status?
Fam-trastuzumab deruxtecan-nxki (T-DXd) may prove to be beneficial in a variety of treatment-refractory solid tumors that express HER2, according to findings from the international phase II DESTINY-PanTumor02 trial presented at the 2023 ASCO Annual Meeting.1 For patients with the highest HER2...
Expert Point of View: Ann S. LaCasce, MD, MMSc
Formal discussant of the SWOG S1826 abstract, Ann S. LaCasce, MD, MMSc, of Dana-Farber Cancer Institute, Boston, said she was “excited” by these results. “The data speak for themselves. Nivolumab plus AVD [doxorubicin, vinblastine, dacarbazine] should be the treatment of choice, with more...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
KEYNOTE-671 Trial: Perioperative Pembrolizumab Plus Chemotherapy Improves Outcomes in Stage II and III NSCLC
Neoadjuvant therapy with pembrolizumab plus platinum-based chemotherapy followed by surgery and then adjuvant pembrolizumab led to significantly improved event-free survival in patients with resectable stage II and III non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
CARTITUDE-4: Ciltacabtagene Autoleucel Beneficial in Early Myeloma Relapse
Compared with the standard of care for relapsed multiple myeloma, a single infusion of ciltacabtagene autoleucel was associated with a significant 74% reduction in the risk of disease progression in patients with lenalidomide-refractory multiple myeloma after one to three relapses, the phase III...
